Application segmentation in the Severe Combined Immunodeficiency (SCID) Diagnosis market distinguishes three primary use cases: newborn screening, clinical diagnosis, and research. Newborn screening, driven by mandatory universal programs in several high‑income countries, accounts for the largest share, estimated at roughly 45 % of total market revenue. Its contribution stems from the need for rapid, high‑throughput assays that can be integrated into existing heel‑prick workflows, thereby generating recurring demand for kits and automation platforms. Clinical diagnosis, representing about 40 % of the market, serves symptomatic infants and older patients; it requires more comprehensive panels, including confirmatory flow‑cytometry and functional assays, which command higher unit prices. The research segment, though smaller at 15 %, underpins assay development and validation, attracting specialized reagents and custom‑design services. Together, these application categories shape the overall market size and dictate distinct pricing, volume, and regulatory dynamics within the Severe Combined Immunodeficiency (SCID) Diagnosis segmentation.